A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

@article{Spackman2008ACA,
  title={A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B},
  author={D. Eldon Spackman and Professor David L. Veenstra},
  journal={PharmacoEconomics},
  year={2008},
  volume={26},
  pages={937-949}
}
Background: A variety of pharmaceuticals are currently approved for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), but their relative economic value is unclear. The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine, pegylated interferon and telbivudine. Methods: We conducted a cost-utility analysis from a US payer perspective over a lifetime time horizon using a Markov model, in a hypothetical population with HBeAg… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 68 REFERENCES

Similar Papers

Loading similar papers…